Lupin Limited (LUPIN) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE326A01037
Key metrics
- Market Cap
- ₹97,489 Cr
- P/E Ratio
- 17.86
- EPS
- 120.69
- Book Value
- 492.44
- P/B Ratio
- 4.33
- ROE
- 23.69%
- ROCE
- 23.41%
- Debt / Equity
- 0.29
- Net Margin
- 19.4%
- Revenue Growth
- 23.86%
- Profit Growth
- 62.51%
- Dividend Yield
- 0.84%
- 52W High
- ₹2,529.50
- 52W Low
- ₹1,900.00
- Market Cap Band
- large cap
- Face Value
- 2
Ratios computed from the annual results period ending 2026-03-31.
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
- Headquarters
- Mumbai, India
- Employees
- 26,021
- Promoter Holding
- 47.02%
The full Lupin Limited analysis
Create a free account to open the complete LUPIN deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.